Market Scope

Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis

Choose Your Experience

Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis

Latest Market Reports

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.

Latest Industry News & Trends

12/5/2025
BreakingCataractDealsDry EyeFLACSGlaucomaIOLPharmaSurgical
Bausch + Lomb Outlines Growth Plans, Driven by Deep Pipeline
Bausch + Lomb Outlines Growth Plans, Driven by Deep Pipeline

Bausch + Lomb used its investor day on Nov. 13 to lay out how it plans to produce growth of 6 to 8 percent in its surgical segment and 5 to 7 percent in its pharmaceutical, consumer, and contact le...

12/5/2025
BreakingDealsDry Eye
Iolyx Licenses Autoimmune Dry Eye Candidate to Théa in Deal Worth Up to $280 Million
Iolyx Licenses Autoimmune Dry Eye Candidate to Théa in Deal Worth Up to $280 Million

Iolyx Therapeutics announced Dec. 3 that it had granted rights worldwide, excluding Asia, to France’s Laboratoires Théa to develop and commercialize ILYX-002, an immune-modulating eye drop candidat...

12/5/2025
BreakingCataractDealsPharma
Formosa Licenses Clobetasol Drops to Rxilient for Countries in Southeast Asia
Formosa Licenses Clobetasol Drops to Rxilient for Countries in Southeast Asia

Taiwan-based Formosa Pharmaceuticals announced Dec. 3 that it had agreed to license to Rxilient Medical exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inflammatio...

12/5/2025
BreakingPharmaRegulation
CDER Chief Pazdur Retiring from US FDA; Makary Names Høeg as Replacement
CDER Chief Pazdur Retiring from US FDA; Makary Names Høeg as Replacement

Oncologist Richard Pazdur, MD, is reportedly retiring from his role as the US FDA’s director of the Center for Drug Evaluation and Research (CDER) after less than a month in the job. The FDA announ...

12/5/2025
BreakingIndustryRetina
Clearside to Pursue Strategic Sale Through Chapter 11 Process
Clearside to Pursue Strategic Sale Through Chapter 11 Process

Clearside Biomedical announced Nov. 24 that it had filed for Chapter 11 bankruptcy protection and intended to pursue an auction and sale of its business. Clearside, of Alpharetta, Georgia, had repo...

12/5/2025
BreakingDealsGlaucomaPharmaRegulation
Ocuvex Resubmits NDA to US FDA for Once-Daily Brimonidine Drop
Ocuvex Resubmits NDA to US FDA for Once-Daily Brimonidine Drop

India’s Sun Pharma Advanced Research Company (SPARC) announced Nov. 20 that its partner Ocuvex had resubmitted the new drug application to the US FDA for PDP-716, a once-daily eye drop formulation ...

12/5/2025
BreakingIndustry
RVL Pharmaceuticals, Maker of Upneeq, Appoints Lori Deo as CEO
RVL Pharmaceuticals, Maker of Upneeq, Appoints Lori Deo as CEO

RVL Pharmaceuticals, of Bridgewater, New Jersey, announced Nov. 24 that it had appointed Lori Deo as chief executive officer. Deo had served as executive chairwoman of the board prior to the appoin...

12/5/2025
BreakingIndustryRetina
Visara Appoints Cadmus Rich, MD, MBA, as Chief Medical Officer
Visara Appoints Cadmus Rich, MD, MBA, as Chief Medical Officer

NovaBridge Biosciences announced Nov. 20 that its ophthalmic subsidiary, Visara, had appointed ophthalmologist Cadmus Rich, MD, MBA, as its chief medical officer (CMO). Visara acquired VIS-101, for...

Provider Surveys & Interviews

Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Table of Innovation

Choose Your Own Adventure

Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.

Safe, Secure & On Any Device

We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.

Pre-Qualified Invitations

We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.

Better Data = Better Decisions

A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.

Market Scope+ App Screen

Market Scope Methodology

A Multi-Step Approach for Accurate & Timely Data

Proprietary data

  • 20+ years of physician survey data
  • Disease models
  • Cultivated database of physicians, ASCs, and hospitals
  • Insight from our team of in-house industry experts

Public data

  • Attendance and participation at major, worldwide meetings
  • Public health systems and registries
  • Clinical study data
  • Analysis of company-published financial reports

Join Market Scope Today

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more

Register A Clinical Account

A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.

Select your country...